文献速递炎症性肠病消化道肿瘤与早癌

腹部或盆腔放疗对炎症性肠病疾病活动度的影响:GETAID多中心队列研究

Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
PubMed 文献 · Aliment Pharmacol Ther · 2020-11-26

该回顾性多中心研究纳入61例接受腹部或盆腔放疗的炎症性肠病患者,按学期评估放疗前后疾病活动度。放疗后各学期IBD活动率与放疗前相比无显著差异,1年和3年无 flare 生存率分别为82.5%和70.6%。中重度急性放疗诱导肠毒性和未联用化疗与 flare 风险增加独立相关。

要点

  • 多数非活动期IBD患者可安全接受腹部或盆腔放疗。
  • 中重度急性放疗诱导肠毒性及未联用化疗者放疗后应更密切监测。
  • 放疗后各学期IBD活动率较放疗前无显著差异。

核心结论

  • 多数非活动期炎症性肠病患者可安全接受腹部或盆腔放疗。
  • 伴有急性肠毒性及未联用化疗的患者在放疗后期间应更密切监测。

研究设计与样本

  • 回顾性多中心研究,纳入61例接受腹部或盆腔放疗的炎症性肠病患者(32例女性,平均年龄59岁),共467个患者学期随访。
  • 按学期(6个月期间)收集放疗前(S-4至S-1)和放疗后(S+1至S+6)的IBD活动度及随访期间IBD flare。
  • 患者因消化道肿瘤(n=31)、泌尿系肿瘤(n=23)和妇科肿瘤(n=7)接受治疗。

主要发现

  • 每学期IBD活动率分别为:S-4至S-1为21%(95%CI:16-27);S+1至S+3为12%(7-19)(对比S-4至S-1,P=0.15);S+4至S+6为16%(10-25)(对比S-4至S-1,P=0.45)。
  • 中位随访156周(四分位距:82-365),放疗后1年和3年无IBD flare生存率分别为82.5%(73.2-93.0)和70.6%(58.8-84.7)。
  • 中重度急性放疗诱导肠毒性和未联用化疗与flare风险增加独立相关。

临床怎么用

  • 多数非活动期IBD患者可安全接受腹部或盆腔放疗;伴有急性肠毒性及未联用化疗的患者在放疗后期间应更密切监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abdominal or pelvic radiotherapy in inflammatory bowel disease (IBD) patients raises concerns regarding the risk of worsening of underlying disease. AIM: To assess the impact of radiotherapy on IBD course. METHODS: A retrospective multicentre study including IBD patients exposed to abdominal or pelvic irradiation was conducted, retrieving IBD activity by semester (6-month periods) before (from S-4 to S-1) and after (from S + 1 to S + 6) radiotherapy and IBD flare during follow-up. RESULTS: Sixty-one patients (32 women, mean age 59 years), with 467 patient semesters of follow-up, treated for digestive (n = 31), urinary tract (n = 23) and gynaecological cancers (n = 7) were included. Rates of IBD activity per semester were, respectively, 21% (95% CI: 16-27) from S-4 to S-1; 12% (7-19) from S + 1 to S + 3 (P = 0.15 vs S-4 to S-1) and 16% (10-25) from S + 4 to S + 6 (P = 0.45 vs S-4 to S-1). With a median follow-up of 156 weeks (interquartile range: 82-365), rates of survival without IBD flare at 1 and 3 years after radiotherapy were 82.5% (73.2-93.0) and 70.6% (58.8-84.7). Moderate-to-severe acute radiotherapy-induced gut toxicity and the absence of concomitant chemotherapy were independently associated with an increased risk of flare. CONCLUSION: Most patients with non-active IBD can be safely treated with abdominal or pelvic radiotherapy. Patients having acute gut toxicity and those without concomitant chemotherapy should be more closely monitored in the post-radiotherapy period.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Broussard D, Rivière P, Bonnet J, et al. Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID. Aliment Pharmacol Ther. 2020. PMID: 33241906. doi:10.1111/apt.16176

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。